Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Atrial effective refractory period"'
Autor:
Ryuichi Kambayashi, Ai Goto, Mayu Onozato, Hiroko Izumi-Nakaseko, Yoshinori Takei, Akio Matsumoto, Shinichi Kawai, Takeshi Fukushima, Atsushi Sugiyama
Publikováno v:
Journal of Pharmacological Sciences, Vol 148, Iss 1, Pp 179-186 (2022)
Since information of antiviral drug oseltamivir on the anti-atrial fibrillation (AF) property is still limited, we assessed it using the canine paroxysmal AF model. Oseltamivir in doses of 3 and 30 mg/kg/10 min was intravenously infused to the isoflu
Externí odkaz:
https://doaj.org/article/2f33f0d0210d45fd9ff92aaa89defa9c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Or Levi, Roni Gillis, Hadar Klapper-Goldstein, Michael Murninkas, Danielle I. Lee, Rotem Polak, Yoram Etzion, Sigal Elyagon, Wesam Mulla, Nikhil S. Bhandarkar
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 320:H713-H724
The complex pathophysiology of atrial fibrillation (AF) is governed by multiple risk factors in ways that are still elusive. Basic electrophysiological properties, including atrial effective refractory period (AERP) and conduction velocity, are major
Autor:
Akio Matsumoto, Eric Chun Yong Chan, Yoshio Nunoi, Mihoko Hagiwara-Nagasawa, Hiroko Izumi-Nakaseko, Ryuichi Kambayashi, Gopalakrishnan Venkatesan, Yoshinori Takei, Ai Goto, Atsushi Sugiyama
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 394:1103-1112
Poyendarone, a deuterated analogue of dronedarone, is expected to reduce the onset of cardiovascular adverse events of dronedarone, including congestive heart failure and excessive QT-interval prolongation. Since information is still lacking on the a
Autor:
Alexander Burashnikov
Publikováno v:
Journal of Cardiovascular Pharmacology
Antiarrhythmic drugs remain the mainstay therapy for patients with atrial fibrillation (AF). A major disadvantage of the currently available anti-AF agents is the risk of induction of ventricular proarrhythmias. Aiming to reduce this risk, several at
Autor:
Akio Matsumoto, Takeshi Fukushima, Atsushi Sugiyama, Ryuichi Kambayashi, Shinichi Kawai, Mayu Onozato, Ai Goto, Hiroko Izumi-Nakaseko, Yoshinori Takei
Publikováno v:
Journal of Pharmacological Sciences, Vol 148, Iss 1, Pp 179-186 (2022)
Since information of antiviral drug oseltamivir on the anti-atrial fibrillation (AF) property is still limited, we assessed it using the canine paroxysmal AF model. Oseltamivir in doses of 3 and 30 mg/kg/10 min was intravenously infused to the isoflu
Publikováno v:
JACC: Basic to Translational Science
JACC: Basic to Translational Science, Vol 4, Iss 4, Pp 546-562 (2019)
JACC: Basic to Translational Science, Vol 4, Iss 4, Pp 546-562 (2019)
Highlights • Derangement of autonomic nervous signaling is an important contributor to cardiac arrhythmogenesis. • Modulation of autonomic nervous signaling holds significant promise for the prevention and treatment of cardiac arrhythmias. • Fu
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association, 9(23). Wiley
Journal of the American Heart Association, 9(23). Wiley
Patients diagnosed with the same subtype of atrial fibrillation according to our current classification system may differ in symptom severity, severity of the arrhythmogenic substrate, and response to antiarrhythmic therapy. Hence, there is a need fo
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.